TY - JOUR
T1 - A Multicountry Molecular Analysis of Salmonella enterica Serovar Typhi with Reduced Susceptibility to Ciprofloxacin in Sub-Saharan Africa
AU - Al-Emran, Hassan M.
AU - Eibach, Daniel
AU - Krumkamp, Ralf
AU - Ali, Mohammad
AU - Baker, Stephen
AU - Biggs, Holly M.
AU - Bjerregaard-Andersen, Morten
AU - Breiman, Robert F.
AU - Clemens, John D.
AU - Crump, John A.
AU - Cruz Espinoza, Ligia Maria
AU - Deerin, Jessica
AU - Dekker, Denise Myriam
AU - Gassama Sow, Amy
AU - Hertz, Julian T.
AU - Im, Justin
AU - Ibrango, Samuel
AU - Von Kalckreuth, Vera
AU - Kabore, Leon Parfait
AU - Konings, Frank
AU - Løfberg, Sandra Valborg
AU - Meyer, Christian G.
AU - Mintz, Eric D.
AU - Montgomery, Joel M.
AU - Olack, Beatrice
AU - Pak, Gi Deok
AU - Panzner, Ursula
AU - Park, Se Eun
AU - Razafindrabe, Jean Luco Tsiriniaina
AU - Rabezanahary, Henintsoa
AU - Rakotondrainiarivelo, Jean Philibert
AU - Rakotozandrindrainy, Raphaël
AU - Raminosoa, Tiana Mirana
AU - Schütt-Gerowitt, Heidi
AU - Sampo, Emmanuel
AU - Soura, Abdramane Bassiahi
AU - Tall, Adama
AU - Warren, Michelle
AU - Wierzba, Thomas F.
AU - May, Jürgen
AU - Marks, Florian
N1 - Publisher Copyright:
© 2016 The Author.
PY - 2016/3/15
Y1 - 2016/3/15
N2 - Background. Salmonella enterica serovar Typhi is a predominant cause of bloodstream infections in sub-Saharan Africa (SSA). Increasing numbers of S. Typhi with resistance to ciprofloxacin have been reported from different parts of the world. However, data from SSA are limited. In this study, we aimed to measure the ciprofloxacin susceptibility of S. Typhi isolated from patients with febrile illness in SSA. Methods. Febrile patients from 9 sites within 6 countries in SSA with a body temperature of ≥38.0°C were enrolled in this study. Blood samples were obtained for bacterial culture, and Salmonella isolates were identified biochemically and confirmed by multiplex polymerase chain reaction (PCR). Antimicrobial susceptibility of all Salmonella isolates was performed by disk diffusion test, and minimum inhibitory concentrations (MICs) against ciprofloxacin were measured by Etest. All Salmonella isolates with reduced susceptibility to ciprofloxacin (MIC > 0.06 μg/mL) were screened for mutations in quinolone resistance-determining regions in target genes, and the presence of plasmid-mediated quinolone resistance (PMQR) genes was assessed by PCR. Results. A total of 8161 blood cultures were performed, and 100 (1.2%) S. Typhi, 2 (<0.1%) Salmonella enterica serovar Paratyphi A, and 27 (0.3%) nontyphoid Salmonella (NTS) were isolated. Multidrug-resistant S. Typhi were isolated in Kenya (79% [n = 38]) and Tanzania (89% [n = 8]) only. Reduced ciprofloxacin-susceptible (22% [n = 11]) S. Typhi were isolated only in Kenya. Among those 11 isolates, all had a Glu133Gly mutation in the gyrA gene combined with either a gyrA (Ser83Phe) or gyrB mutation (Ser464Phe). One Salmonella Paratyphi A isolate with reduced susceptibility to ciprofloxacin was found in Senegal, with 1 mutation in gyrA (Ser83Phe) and a second mutation in parC (Ser57Phe). Mutations in the parE gene and PMQR genes were not detected in any isolate. Conclusions. Salmonella Typhi with reduced susceptibility to ciprofloxacin was not distributed homogenously throughout SSA. Its prevalence was very high in Kenya, and was not observed in other study countries. Continuous monitoring of antimicrobial susceptibility is required to follow the potential spread of antimicrobial-resistant isolates throughout SSA.
AB - Background. Salmonella enterica serovar Typhi is a predominant cause of bloodstream infections in sub-Saharan Africa (SSA). Increasing numbers of S. Typhi with resistance to ciprofloxacin have been reported from different parts of the world. However, data from SSA are limited. In this study, we aimed to measure the ciprofloxacin susceptibility of S. Typhi isolated from patients with febrile illness in SSA. Methods. Febrile patients from 9 sites within 6 countries in SSA with a body temperature of ≥38.0°C were enrolled in this study. Blood samples were obtained for bacterial culture, and Salmonella isolates were identified biochemically and confirmed by multiplex polymerase chain reaction (PCR). Antimicrobial susceptibility of all Salmonella isolates was performed by disk diffusion test, and minimum inhibitory concentrations (MICs) against ciprofloxacin were measured by Etest. All Salmonella isolates with reduced susceptibility to ciprofloxacin (MIC > 0.06 μg/mL) were screened for mutations in quinolone resistance-determining regions in target genes, and the presence of plasmid-mediated quinolone resistance (PMQR) genes was assessed by PCR. Results. A total of 8161 blood cultures were performed, and 100 (1.2%) S. Typhi, 2 (<0.1%) Salmonella enterica serovar Paratyphi A, and 27 (0.3%) nontyphoid Salmonella (NTS) were isolated. Multidrug-resistant S. Typhi were isolated in Kenya (79% [n = 38]) and Tanzania (89% [n = 8]) only. Reduced ciprofloxacin-susceptible (22% [n = 11]) S. Typhi were isolated only in Kenya. Among those 11 isolates, all had a Glu133Gly mutation in the gyrA gene combined with either a gyrA (Ser83Phe) or gyrB mutation (Ser464Phe). One Salmonella Paratyphi A isolate with reduced susceptibility to ciprofloxacin was found in Senegal, with 1 mutation in gyrA (Ser83Phe) and a second mutation in parC (Ser57Phe). Mutations in the parE gene and PMQR genes were not detected in any isolate. Conclusions. Salmonella Typhi with reduced susceptibility to ciprofloxacin was not distributed homogenously throughout SSA. Its prevalence was very high in Kenya, and was not observed in other study countries. Continuous monitoring of antimicrobial susceptibility is required to follow the potential spread of antimicrobial-resistant isolates throughout SSA.
KW - S. Typhi
KW - ciprofloxacin
KW - sub-Saharan Africa
KW - susceptible
UR - http://www.scopus.com/inward/record.url?scp=84959871745&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959871745&partnerID=8YFLogxK
U2 - 10.1093/cid/civ788
DO - 10.1093/cid/civ788
M3 - Article
C2 - 26933020
AN - SCOPUS:84959871745
SN - 1058-4838
VL - 62
SP - s42-s46
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
ER -